New Treatments & Clinical Trials for Acute Myeloid Leukemia

Acute myeloid leukemia is a fast-growing blood cancer that starts in the bone marrow and crowds out healthy blood cells. It affects about 20,000 Americans each year, mostly adults over 65. Standard treatment combines chemotherapy with stem cell transplant when possible, but outcomes vary widely depending on genetic factors in the leukemia cells.

What's actually going on in research

Trials are testing targeted drugs that attack specific mutations in AML cells—FLT3 inhibitors, IDH inhibitors, and menin inhibitors are showing promise. Researchers are also studying better conditioning regimens before transplant, maintenance therapy to prevent relapse after remission, and ways to overcome treatment resistance. CAR-T cell therapy and antibody-drug conjugates are being adapted from other blood cancers.

What to know before you search

Eligibility usually depends on whether this is newly diagnosed or relapsed AML, specific mutations in the leukemia cells, age, fitness for intensive chemotherapy, and prior treatments received.

What types of trials are currently open

• Frontline treatment trials — Testing new combinations of chemotherapy and targeted drugs for people newly diagnosed with AML, often comparing them to standard chemotherapy regimens.
• Relapsed/refractory trials — Studies of newer drugs for AML that has returned or didn't respond to initial treatment, where options are more limited and experimental approaches may be the best path.
• Maintenance therapy trials — Testing drugs given after achieving remission to prevent relapse, particularly for people who can't undergo transplant.
• Transplant studies — Trials testing conditioning regimens, graft-versus-host disease prevention, and post-transplant strategies to reduce relapse risk.
• Molecular subtype trials — Studies focused on specific genetic mutations in AML, testing drugs designed to target those exact changes in the cancer cells.